| Literature DB >> 31754302 |
Blanka Klimova1, Michal Novotný2, Kamil Kuca2,3,4, Martin Valis5.
Abstract
Currently, there is an increase in the number of the world's aging population. This aging process is often connected with cognitive decline of some functions such as memory or speed processing loss. Since Alzheimer's disease cannot be cured yet, considerable efforts are being made to at least delay this cognitive decline among elderly in order to maintain and prolong the quality of their life. This can also be achieved by non-pharmacological approaches such as performing physical activities, cognitive training, or adhering to a Mediterranean Diet (MedDiet). One of the components of MedDiet - extra-virgin olive oil (EVOO) - has considerable health benefits. The purpose of this review is to examine the effect of EVOO intake on the delay of cognitive decline among the elderly. The methodology is based on a literature review of available sources found on the research topic in three acknowledged databases: Web of Science, Scopus, and PubMed. The results of in vitro and in vivo studies indicate that the regular intake of EVOO is associated with enhanced cognitive functions, which means that this oil may have a neuroprotective effect and could positively prevent the development of dementia, especially Alzheimer's dementia. It is believed that secoiridoid oleuropein is responsible for this effectiveness. Furthermore, there is also a need of more randomized controlled studies or longitudinal observational studies to be performed to confirm the efficacy of the beneficial health effect of EVOO on the delay of cognitive decline.Entities:
Keywords: Alzheimer disease; cognitive decline; extra-virgin olive oil; oleuropein; oleuropein-aglycone; review
Year: 2019 PMID: 31754302 PMCID: PMC6825477 DOI: 10.2147/NDT.S218238
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Figure 1Chemical formula of oleuropein.
Figure 2Chemical formula of oleuropein-aglycone.
The Most Important Effects Of Oleuropein
| Property | Observed Effects | References |
|---|---|---|
| Antioxidant | Inhibits of oxidation of low-density lipoproteins (LDL) | |
| Scavenges nitric oxide; increase inducible nitric oxide synthase expression | ||
| Induction of the inducible nitric oxide synthase in macrophages | ||
| Increases the ability of LDL to resist oxidation; reduces the plasma levels of total, free, and esterified cholesterol | ||
| Antioxidant effects in leukocytes | ||
| Lower lipid peroxidation | ||
| Anti-inflamatory | Inhibitis lipoxygenase activity and the production of leukotriene B4 | |
| Anti-atherogenic | Reduces monocytoid cell adhesion to endothelium and reduces | |
| Anti-cancer | Inhibits growth cancer cells (LN-18, TF-1a, 786-O, T-47D, RPMI-7951, LoVo) | |
| Decreases breast cancer cell viability | ||
| Reduces the viability of MCF-7 by inducing cell apoptosis | ||
| Inhibits cell proliferation (MCF-7, T-24, BBCE) | ||
| Anti-microbial | Strong antimicrobial activity against gram-negative and gram-positive bacteria | |
| Antimicrobial activity against mycoplasma | ||
| Able to inhibit the development of: Staphylococcus aureus, Salmonella enteritidis, Bacillus cereus, Klebsiella pneumoniae, Escherichia coli, Campylobacter jejuni, Helicobacter pylori | ||
| Antiviral | Antiviral against: herpes mononucleosis, hepatis virus, rotavirus, bovine rhinovirus, canine parvovirus, feline leukemia virus | |
| Antiviral against: respiratory syncytial virus and para-influenza type 3 virus |
Currently Ongoing Studies Of Olive Oil, EVOO, Or Oleuropein ()
| NCT Number | Title | Status | Conditions | Enrollment | Start Date |
|---|---|---|---|---|---|
| NCT03779529 | EVOO Coratina Intervention on Lipids in Non-diabetic Hypertensive Patients Undergoing Hemodialysis | Recruiting | Chronic Kidney Disease Stage V | 24 | July 1, 2018 |
| NCT03820336 | Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women | Not yet recruiting | Hypertension; Vascular Stiffness | 40 | February 2019 |
| NCT03824197 | Auburn University Research on Olive Oil for Alzheimer’s Disease | Not yet recruiting | Alzheimer Disease; Cerebral Amyloid Angiopathy | 30 | February 2019 |
| NCT03408847 | Monocultivar Coratina Extra Virgin Olive Oil in UC Patients | Recruiting | Ulcerative Colitis Chronic Mild | 30 | November 20, 2017 |
| NCT03528603 | Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal | Recruiting | Platelet Aggregation; Nutritional and Metabolic Disease; Cardiovascular Diseases | 50 | April 2, 2018 |
| NCT03053843 | Mediterranean Diet Plus Extra-virgin Olive Oil in the Prevention of Recurrent Arrhythmias | Recruiting | Atrial Fibrillation; Atrial Arrhythmia | 640 | March 22, 2017 |
| NCT03891927 | Extra Virgin Olive Oil on Glycemic Control, Insulin Resistance and Insulin Secretion | Not yet recruiting | Insulin Resistance | 80 | May 1, 2019 |
| NCT03081065 | Mediterranean Diet and Recurrence of Depression | Not yet recruiting | Depression | 750 | March 20, 2017 |
| NCT03447301 | The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients | Not yet recruiting | Type 2 Diabetes Mellitus | 400 | February 25, 2018 |
| NCT03362996 | Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil | Recruiting | Mild Cognitive Impairment | 150 | November 9, 2016 |
| NCT03796780 | Comparison of Extra-Virgin and Refined Olive Oil on Some Cardiovascular Risk Factors | Recruiting | Cardiovascular Risk Factor | 40 | January 1, 2019 |
| NCT03024359 | Monounsaturated Fatty Acids and Brown/Beige Adipose Tissue in Humans | Recruiting | Obese | 50 | January 2017 |
Animal Studies Of Oleuropein In Neuroprotection
| Animal | Result | References |
|---|---|---|
| C57B1/6J mice | Enhanced contextual memory; reduced age-related impairment in motor coordination; lipid peroxidation and inflammation markers were decreased in brain areas connected with motor control | |
| TgCRND8 mice | Ameliorated memory dysfunction; reduced β-amyloid levels and plaque deposits; increase of autophagic markers expression through mTOR inhibition | |
| TgCRND8 mice | Massive reduction of pyroglutamate-3 amyloid-β protein (major component of β-amyloid plaque) by reducing its aggregation | |
| Wistar rat | Reduced the toxicity of Aβ aggregated; reduced the amount of soluble Aβ oligomers; no evident inflammatory reaction | |
| CL2600 Caenorhabditis elegans | Reduction in the plaque deposition; less abundant toxic Aβ oligomers |